64th ASH Annual Meeting and Exposition: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, artificial intelligence (AI), Fundamental Science, clinical trials, adult, Translational Research, Plasma Cell Disorders, genomics, bioinformatics, Combination therapy, Clinical Research, Diseases, patient-reported outcomes, Therapies, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures, Study Population, Human, pathogenesis, Minimal Residual Disease , machine learning, molecular testing, omics technologies

New Orleans Theater C (Ernest N. Morial Convention Center)

Moderators:

Natalia Neparidze, MD, Yale University School of Medicine and Yale Cancer Center and Aurore Perrot, MD, PhD, CHU de Toulouse, IUCT-O, Université de Toulouse

Disclosures:

Neparidze: GSK: Research Funding; Janssen: Research Funding. Perrot: Abbvie: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

This session will highlight recent efforts at refining and improving prognostic assessments in Multiple Myeloma. Dr. Cirrincione will present the genomic data suggesting alternative, previously unknown myeloma-initiating events paving the way toward further exploration of large datasets with novel analytical methods. Dr. Kaiser will present data on the utility of extended genetic profiling based on the meta-analysis of molecular events from several randomized clinical trials. Dr. Poletti will focus on defining a novel methodological framework aimed at the identification of copy-number signatures and their biological significance in myeloma. Dr. Maura will describe the first artificial intelligence prediction model for newly diagnosed multiple myeloma (NDMM) to guide individual treatment decisions. Dr. Terpos will highlight the role of next-generation flow cytometry assessment of circulating tumor cells as a potential independent prognostic marker for risk stratification for NDMM. Dr. Hofste op Bruinink will present the study evaluating combination of plasma cell leukemia-like status with the R2-ISS classification to improve prognostic accuracy in high-risk NDMM.

4:30 PM

643

Tracking the Earliest Genomic Events in Multiple Myeloma Life-History

Anthony Cirrincione, PhD¹^*, Bachisio Ziccheddu, PhD¹^*, Kylee H Maclachlan, MBBCh, PhD², Alexandra M. Poos, PhD³^*, Monika Chojnacka, BS¹, Benjamin Diamond, MD¹, Eileen M Boyle, MD, PhD⁴, Patrick Blaney, MS⁴^*, Dylan Gagler, MS⁴^*, Yanming Zhang⁵^*, Ahmet Dogan, MD, PhD⁶, Alexander M Lesokhin, MD², Faith E. Davies, MD⁴^*, Neha Korde, MD⁷, Marc S Raab, MD³^*, Niels Weinhold, PhD³^*, Saad Usmani, MD², Gareth J. Morgan, MD⁴, Ola Landgren, MD¹ and Francesco Maura, MD⁸

¹Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
²Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
³Multiple Myeloma Research Group, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
⁴Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, NY
⁵Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, NY
⁸Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, PALMETTO BAY, FL

4:45 PM

644

Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients – Meta-Analysis of 5,808 Trial Patients

Martin F. Kaiser, MD, FRCP, FRCPath^1,2, Pieter Sonneveld, MD³, David Cairns, PhD⁴^*, Marc S Raab, MD⁵^*, Alessandra Larocca, MD, PhD⁶, Sarah R Brown, PhD, MSc, BSc⁴^*, Marc-A. Baertsch, MD⁷^*, Cong Li, PhD⁸^*, Pellegrino Musto, MD⁹, Kwee Yong¹⁰^*, Elias K Mai, MD¹¹^*, Andrea Capra¹²^*, Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath⁴^*, Hartmut Goldschmidt, MD^11,13, Mario Boccadoro, MD¹⁴, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM¹⁵, Niels Weinhold, PhD¹¹^* and Francesca Gay, MD, PhD¹⁶^*

¹The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
²Myeloma Molecular Therapy Group, The Institute of Cancer Research, London, United Kingdom
³Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
⁴Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
⁵Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
⁶Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
⁷Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
⁸Takeda Development Center Americas, Inc, Deerfield, IL
⁹Hematology Section, Department of Emergency and Transplantation, University of Bari Medical School, Bari, Italy
¹⁰Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
¹¹Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
¹²Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-, Torino, ITA
¹³National Center for Tumor Diseases (NCT), Heidelberg, Germany
¹⁴Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
¹⁵Department of Haematology, University of Newcastle, Newcastle upon Tyne, United Kingdom
¹⁶Division of Hematology, University of Torino, Torino, Italy

5:00 PM

645

A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies

Andrea Poletti, MSc¹^*, Stafano Delle Vedove, MSc¹^*, Gaia Mazzocchetti¹^*, Vincenza Solli^1,2^*, Ajsi Kanapari, MSc¹^*, Enrica Borsi¹^*, Marina Martello¹^*, Giovanni Martinelli, MD^3,4, Silvia Armuzzi¹^*, Ilaria Vigliotta⁵^*, Barbara Taurisano, MSc¹^*, Ignazia Pistis⁵^*, Elena Zamagni^1,5^*, Michele Cavo, MD^1,5^* and Carolina Terragna, PhD^1,5^*

¹"Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
²Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
³Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy
⁴University of Bologna, Meldola, Italy
⁵Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

5:15 PM

646

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Francesco Maura, MD¹, Arjun Raj Rajanna, MSc¹^*, Andriy Derkach, PhD²^*, Bachisio Ziccheddu, PhD³^*, Niels Weinhold, PhD⁴^*, Kylee H Maclachlan, MBBCh, PhD⁵, Benjamin Diamond¹^*, Faith E. Davies, MD⁶^*, Eileen Boyle⁶^*, Brian A. Walker, PhD⁷, Alexandra M Poos, PhD⁴^*, Malin Hultcrantz, MD, PhD⁵, Ariosto Siqueira Silva, PhD⁸^*, Oliver Hampton, PhD⁹^*, Jamie Teer, PhD⁸^*, Niccolo Bolli, MD¹⁰^*, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM¹¹, Martin F. Kaiser, MD, FRCP, FRCPath¹², Charlotte Pawlyn, PhD¹³, Gordon Cook¹⁴^*, Dennis Verducci¹^*, Dickran Kazandjian, MD¹, Frits van Rhee¹⁵, Saad Usmani, MD¹⁶, Ken H. Shain, MD, PhD⁸, Marc S Raab, MD⁴^*, Gareth J. Morgan, MD⁶ and Ola Landgren, MD³

¹Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami
²Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
³Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
⁴Multiple Myeloma Research Group, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
⁵Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁶NYU Langone, Perlmutter Cancer Center, New York
⁷Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN
⁸Department of Malignant Hematology, Moffitt Cancer Center, Tampa
⁹M2GEN, Tampa, FL
¹⁰Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico & University of Milan, Milan, Italy
¹¹Department of Haematology, NCCC Freeman Road Hospital, Newcastle Upon Tyne, United Kingdom
¹²The Institute of Cancer Research, London, ENG, United Kingdom
¹³The Institute of Cancer Research, London, United Kingdom
¹⁴Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
¹⁵Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR
¹⁶Myeloma Service, Memorial Sloan Kettering Cancer Center, New York

5:30 PM

647

Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis

Ioannis V Kostopoulos, PhD¹^*, Panagiotis Malandrakis, MD²^*, Ioannis Ntanasis-Stathopoulos, MD³^*, Pantelis Roussakis, MSc¹^*, Evangelos Eleutherakis Papaiakovou, MD³^*, Chrysanthi Panteli¹^*, Nikolaos Angelis¹^*, Nikolaos Kanellias, MD³^*, Nikolaos Orologas-Stavrou¹^*, Foteini Theodorakakou, MD²^*, Despina Fotiou, MD³^*, Magdalini Migkou, MD³^*, Maria Gavriatopoulou, MD³^*, Efstathios Kastritis, MD³^*, Ourania E. Tsitsilonis, MD, PhD¹^*, Meletios-Athanasios Dimopoulos, MD, PhD⁴ and Evangelos Terpos, MD, PhD³

¹Department of Biology, National and Kapodistrian University of Athens, School of Science, Athens, Greece
²Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
³Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
⁴Plasma Cell Dyscrasias Unit, Section of Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

5:45 PM

648

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Davine Hofste op Bruinink, MD, MSc^1,2^*, Rowan Kuiper, PhD^1,3^*, Mark van Duin, PhD¹^*, Tom Cupedo, PhD¹^*, Vincent H.J. van der Velden, PhD²^*, Remco Hoogenboezem, MSc¹^*, Bronno van der Holt, PhD⁴^*, Berna Beverloo, PhD⁵^*, Erik T. Valent, PhD³^*, Michael Vermeulen, BSc¹^*, Mattia D'Agostino, MD⁶^*, Francesca Gay, MD, PhD⁶^*, Annemiek Broijl, MD, PhD¹^*, Herve Avet-Loiseau, MD, PhD⁷^*, Nikhil C Munshi, MD, PhD⁸, Pellegrino Musto, MD⁹, Philippe Moreau, MD¹⁰^*, Sonja Zweegman, MD, PhD¹¹, Niels W.C.J. van de Donk, MD, PhD¹¹ and Pieter Sonneveld, MD¹

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
³SkylineDx, Rotterdam, Netherlands
⁴HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
⁵Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands
⁶Division of Hematology, University of Torino, Torino, Italy
⁷Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
⁸Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁹Hematology and Stem Cell Transplantation Unit - A.O.U. Consorziale Policlinico di Bari, Bari, Italy
¹⁰Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
¹¹Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652.O2.6 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma